Deanna Csomo McCool | May 25, 2017
Tweaking the immune system with therapies to target and kill cancer cells has been a promising advancement for cancer research, but the current methods used by many companies can unintentionally destroy healthy tissues as well.
The interdisciplinary team of Structured Immunity, however, has patented a new technology that can increase the effectiveness of treatment and lessen the possibility of these side effects. The start-up shared the grand prize in the McCloskey Business Plan competition in April. Structured Immunity was guided by Brian Baker, the John A. Zahm Professor of Structural Biology and chair of the department of chemistry and biochemistry, and researcher with the Mike and Josie Harper Cancer Research Institute, and was developed by David Hardwicke, ESTEEM ’17, Tim Riley PhD. ’17, and Fan Ping, MBA ’17.
The prize came with a $15,000 award, but it’s the exposure to investors that is particularly exciting to the winning team as they now look toward assembling a board of directors and launching their company.